The Hong Kong Stock Exchange recently published a Consultation Paper on a Listing Regime for Companies from Emerging and Innovative Sectors, and proposed to introduce a new chapter implementing the listing of pre-revenue/pre-profit biotech companies on the Main Board of the Exchange.
The Consultation Paper clarifies uncertainties in the previous proposal (particularly on determining whether a product has been developed beyond the concept stage) and enables biotech companies seeking listing in Hong Kong to effectively assess if they could meet the relevant requirements.
Please see full publication below for more information.
